Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PASSAGE BIO INC.
PASG | US
9.89
USD-1.30
-11.62%
PASG | US
About PASSAGE BIO INC.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/04/2026
Close
9.89
Open
11.19
High
11.19
Low
9.50
Passage Bio Inc. a genetic medicines company develops transformative therapies for central nervous system diseases. It develops PBGM01 a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02 a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03 a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement and a development services and clinical supply agreement with Catalent Maryland Inc. The company was incorporated in 2017 and is headquartered in Philadelphia Pennsylvania.
View LessPASG | US
Risk
149.3
Sharpe
0.39
Luna's Score
45/100
Recommendation
Sell
Luna says (PASG | US)
What's Working
Positive Momentum
Value Stock (Price to Book < 3)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
201.4%1 month
149.3%3 months
120.4%6 months
122.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.41
Debt to equity
0.29
Debt to assets
0.21
Ent. to EBITDA
0.87
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-84.65M
MarketCap
610.88M
MarketCap(USD)
610.88M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-63.55
Short ratio
6.28
Short perc.
3.30
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
5.39
Range1M
5.39
Range3M
14.09
Volumes: Market Activity
Rel. volume
1.04
Price X volume
459.52K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.87 | - | Expensive |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.41 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 120.37 | - | Riskier |
| Debt to Equity | 0.29 | -1.23 | Expensive |
| Debt to Assets | 0.21 | 0.25 | Par |
| Market Cap | 610.88M | - | Emerging |
